According to www.cigb.edu.cu, the majestic event will bring together scientists, medical chemists, pharmacologists, biotechnologists, clinical researchers and other professionals interested in the fields of cancer pathogenesis and the development of new targeted therapies.

The International Symposium will be goal-oriented to passive and active anti-angiogenic immunotherapeutic strategies and also to emerging combinations in this field, particularly with immune checkpoint inhibitors.

The website explained that issues related to cancer immunotherapy in angiogenesis, immune checkpoint inhibitors and the targeting of integrins and combination with immune checkpoint inhibitors in the tumor microenvironment will be the focus of discussions among specialists.

The Symposium will also present, among others, ideas concerning translational nature of modern biomedical and pharmaceutical research from different experiences and perspectives.

pll/mem/ads